IDH2 and neoplasm: Whilst the majority of ctDNA mutations were patient-specific, core signalling pathways and groups of therapeutically relevant genes, including IDH family genes, recently highlighted as promising targets for molecular therapy in PDAC in the Know Your Tumour Project (Pancreatic Cancer Action Network) [43], were frequently affected across the cohort.